Regeneron Pharmaceuticals Inc (REGN, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron Pharmaceuticals Inc has a market cap of $41.93 billion; its shares were traded at around $381.87 with a P/E ratio of 20.46 and P/S ratio of 5.75. Regeneron Pharmaceuticals Inc had annual average EBITDA growth of 29.40% over the past five years. GuruFocus has detected 1 severe warning sign with Regeneron Pharmaceuticals Inc. .
For the last quarter Regeneron Pharmaceuticals Inc reported a revenue of $2.2 billion, compared with the revenue of $1.9 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $7.9 billion, an increase of 17.2% from last year. For the complete 30-year financial data, please go here.. For the last five years Regeneron Pharmaceuticals Inc had an average revenue growth rate of 21.4% a year.
The reported diluted earnings per share was $18.46 for the year, a decline of 13.3% from the previous year. Over the last five years Regeneron Pharmaceuticals Inc had an EPS growth rate of 46.9% a year. The Regeneron Pharmaceuticals Inc had a decent operating margin of 28.1%, compared with the operating margin of 37.77% a year before. The 10-year historical median operating margin of Regeneron Pharmaceuticals Inc is 29.87%. The profitability rank of the company is 8 (out of 10).
At the current stock price of $381.87, Regeneron Pharmaceuticals Inc is traded at 41.3% discount to its historical median P/S valuation band of $650.96. The P/S ratio of the stock is 5.75, while the historical median P/S ratio is 9.80. The stock lost 6.05% during the past 12 months.
Directors and Officers Recent Trades:
- EVP Research Andrew J Murphy sold 8,000 shares of REGN stock on 01/27/2020 at the average price of $340.91. The price of the stock has increased by 12.01% since.
For the complete 20-year historical financial data of REGN, click here.
